Page 4 - கெஃப்ஃபெந் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

FINDINGS A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center has identified a novel combination therapy to potentially help overcome resistance to immunotherapy in people diagnosed with advanced lung cancer. The combination approach uses immune checkpoint inhibitors with ATRA, a safe medication that is widely used to treat leukemia. The team found the combination therapy led to eradication of over 70% of tumors when tested in mice with LKB1-deficient lung cancer. It also generated durable tumor-specific immunity. BACKGROUND Immune checkpoint inhibitors have substantially improved the outcomes for people with lung cancer. The five-year survival rate for patients with advanced disease on this therapy is more than 13% compared to 5% in patients with conventional chemotherapy. Although immunotherapy has been successful for many patients, a majority of patients still do not respond to the therapy.

United statesRamin salehi radSteven dubinettGeffen school of medicineCancer researchAmerican association for cancer researchJonsson comprehensive cancer centerComprehensive cancer centerBin liuGeffen schoolComprehensive cancerAmerican associationஒன்றுபட்டது மாநிலங்களில்ராமின் சாலேதி ராட்கெஃப்ஃபெந் பள்ளி ஆஃப் மருந்துபுற்றுநோய் ஆராய்ச்சி